MOTS-c myths: what the research does not show
Cellular Energy & Mitochondrial Research
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, with strong mouse results on metabolism and physical capacity, human studies that measure the body’s own MOTS-c, and no published human trial of giving it. This page separates the mouse findings from the human ones and checks each popular claim against the right set.
Findings
- In mice, MOTS-c prevented diet-induced obesity and age-related insulin resistance (Cell Metab, 2015).
- MOTS-c improved physical performance in young, middle-aged and old mice, and starting it late in life raised physical capacity (Nat Commun, 2021).
- In people, exercise raised the body’s own MOTS-c in muscle and in the blood (same 2021 study).
- The biggest gap: we found no published human trial of MOTS-c given as a compound, for any outcome.
View product →Myth: MOTS-c is exercise in a bottle for humans
Partly true, but only half of it is about humans. The 2021 Nat Commun study showed MOTS-c improved physical performance in mice of three ages, including 22-month-old mice. The human part of that study was different: people who exercised produced more of their own MOTS-c. That links MOTS-c to exercise in humans. It does not show that taking MOTS-c does what exercise does.
Myth: MOTS-c reverses insulin resistance
Shown in mice, unclear in people. The 2015 study that named MOTS-c found it acts mainly on skeletal muscle, activates the energy sensor AMPK and prevented insulin resistance in mice on a high-fat diet and in older mice. A 2025 human study of 85 adults found something less tidy: blood MOTS-c was no lower in people with obesity, and it rose rather than fell with higher insulin resistance. The human picture is not a simple shortage waiting to be topped up.
Myth: MOTS-c causes weight loss
In mice, MOTS-c prevented weight gain on a high-fat diet. Prevention in mice is not the same as weight loss in people, and we found no human trial that measured body weight after MOTS-c was given. The same 2025 human study found no difference in circulating MOTS-c between adults with obesity and those of normal weight.
Myth: MOTS-c is a proven longevity peptide
Partly true as a research lead. In 2021, mice that started MOTS-c late in life gained physical capacity and what the authors called healthspan. A short 2015 paper suggested that a MOTS-c gene variant common in Northeast Asia might help explain Japanese longevity, and it said itself that more research was needed. Neither study measured lifespan in people given MOTS-c.
Myth: more MOTS-c activity always means better muscle
The human genetics hint otherwise. A 2022 study in Japanese adults looked at the East Asian K14Q variant, which makes a less active form of MOTS-c. Carriers had more fast-twitch muscle fibre, men with it produced higher leg torque, and the variant was more common in sprint and power athletes than in endurance athletes. Lower MOTS-c activity went with a different kind of muscle, not a weaker one.
Myth: MOTS-c is safe because the body makes it
The body does make MOTS-c, which is why the human exercise data exist. But natural production at normal levels is not the same as giving a synthetic version, and that has not been studied in published human trials. A 2026 sports medicine review included MOTS-c among unapproved peptides for which rigorous human safety data are scarce.
What MOTS-c cannot promise
MOTS-c is one of the most interesting discoveries in mitochondrial biology. The evidence for giving it is still entirely in animals.
- It cannot promise better fitness in people; that was shown in mice.
- It cannot promise reversal of insulin resistance in people; human levels do not follow the simple pattern.
- It cannot promise weight loss; no human trial measured it.
- It cannot promise longer life; lifespan was not studied in people.
Where the evidence stands
MOTS-c is not an approved medicine in Canada for any use. Its research consists of cell and mouse work plus human studies of natural MOTS-c levels and gene variants. No human trial of MOTS-c given as a compound has been published. Synthetic MOTS-c is supplied for laboratory research only.
Vistara Labs supplies MOTS-c as a laboratory research material. The page above is about the published research, not a claim about our product.
Frequently asked questions
Has MOTS-c been tested in humans?
Not as a compound given to people, as far as we found. Human studies have measured natural MOTS-c, which rose with exercise, and a MOTS-c gene variant linked to muscle fibre type.
Does MOTS-c improve exercise performance?
In mice, yes: a 2021 study found better physical performance in young, middle-aged and old mice. In people, exercise raises natural MOTS-c, but no trial has given MOTS-c and measured performance.
Is MOTS-c low in people with obesity?
A 2025 study of 85 adults found no significant difference in blood MOTS-c between people with obesity and those of normal weight. MOTS-c fell with age and rose with insulin resistance.
Sources: Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PMID 25738459. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. PMID 33473109. Ozkaya DY, Haymana C, Demirci I, et al. MOTS-c levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction. Arch Endocrinol Metab. 2025. PMID 41004666. Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015. PMID 26289118. Kumagai H, Natsume T, Kim SJ, et al. The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance. Biochim Biophys Acta Gen Subj. 2022. PMID 34728329. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026. PMID 41966639.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
References
Human MOTS-c studies measure the peptide the body already makes; no controlled trial administering native synthetic MOTS-c was identified. (CB4211, which has completed phase 1, is an optimised analogue, not native MOTS-c.)
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceFoundational paper identifying MOTS-c; laboratory studies of insulin sensitivity and diet-induced obesity.
- Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humansHuman study measuring naturally occurring (endogenous) mitochondrial-derived peptides after acute endurance exercise — not administration of synthetic MOTS-c.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
